These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 14727222)

  • 1. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML
    Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
    J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Soriano A; Marco F; Martínez JA; Pisos E; Almela M; Dimova VP; Alamo D; Ortega M; Lopez J; Mensa J
    Clin Infect Dis; 2008 Jan; 46(2):193-200. PubMed ID: 18171250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
    Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
    N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
    Sakoulas G; Moellering RC
    Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia.
    Khosrovaneh A; Riederer K; Saeed S; Tabriz MS; Shah AR; Hanna MM; Sharma M; Johnson LB; Fakih MG; Khatib R
    Clin Infect Dis; 2004 May; 38(9):1328-30. PubMed ID: 15127350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia.
    Sakoulas G; Gold HS; Cohen RA; Venkataraman L; Moellering RC; Eliopoulos GM
    J Antimicrob Chemother; 2006 Apr; 57(4):699-704. PubMed ID: 16464892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.
    Sader HS; Jones RN; Rossi KL; Rybak MJ
    J Antimicrob Chemother; 2009 Nov; 64(5):1024-8. PubMed ID: 19744978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
    Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
    J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G; White R; Friedrich L
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.
    Hegde SS; Difuntorum S; Skinner R; Trumbull J; Krause KM
    J Antimicrob Chemother; 2009 Apr; 63(4):763-6. PubMed ID: 19155225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem.
    Jang HC; Kim SH; Kim KH; Kim CJ; Lee S; Song KH; Jeon JH; Park WB; Kim HB; Park SW; Kim NJ; Kim EC; Oh MD; Choe KW
    Clin Infect Dis; 2009 Aug; 49(3):395-401. PubMed ID: 19569970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia.
    Maor Y; Hagin M; Belausov N; Keller N; Ben-David D; Rahav G
    J Infect Dis; 2009 Mar; 199(5):619-24. PubMed ID: 19199552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key considerations in the treatment of complicated staphylococcal infections.
    Jones RN
    Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
    Ahmad NM; Rojtman AD
    Ann Pharmacother; 2010 May; 44(5):918-21. PubMed ID: 20354160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG; Gao W; Ward PB; Howden BP
    J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous vancomycin-resistant Staphylococcus aureus (hetero-VISA) in Singapore.
    Sng LH; Koh TH; Wang GC; Hsu LY; Kapi M; Hiramatsu K
    Int J Antimicrob Agents; 2005 Feb; 25(2):177-9. PubMed ID: 15664490
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 40.